Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Norwich Pharmaceuticals, a full-service contract development and manufacturing company, has formed Norwich Clinical Services to provide clinical testing capabilities that will further expand the company's third party services.
Subscribe to our email newsletter
Norwich Clinical Services is expected to offer a complete range of clinical research capabilities including Phase I – IV trials, bioanalytical studies and pharmacovigilance monitoring services.
Norwich Clinical Services initially is expected to offer customers pharmacovigilance monitoring supported by Oracle AERS software, bioanalytical studies utilising API 4000 LC/MS systems, and medical writing services.
Norwich Pharmaceuticals said that an independent, 60-bed, clinical trial facility will open later this year that possesses the instrumentation and expertise to conduct pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
Saral Thangam, managing director of Norwich Clinical Services, will lead an experienced team of professionals who each have at least 15 years’ experience in clinical research and life sciences.
Doug Drysdale, CEO of Alvogen, said: “The introduction of Norwich Clinical Services underscores our strategic focus to provide customers with a comprehensive solution for all stages of product life cycle management. We have assembled the highest level of professional expertise to ensure Norwich Clinical Services matches our tradition of unparalleled quality standards and delivers contract pharmaceutical services with everyday excellence.
“We are extremely pleased to be generating new products, services and opportunities at Norwich. Norwich Clinical Services will be a pivotal component for growing our business as we continue to expand capabilities to meet the demands associated with new markets.”
Mr Thangam said: “Our success will be guided by a team that is highly experienced in clinical research, having completed more than 50 clinical trial programs and 2,000 bioanalytical studies.”